Drugs / Pradigastat
Pradigastat
English name pradigastat
also known as
LCQ908 · Lcq-908 sodium salt · LCQ-908-ABA · LCQ-908-NXA · Lcq908 - dgat-1-inhibitor · LCQ908A · PRADIGASTAT SODIUM
Small molecule targets DGAT1 via inhibition
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01558323 | May 2012 → Mar 2013 | impaired renal function disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01594957 | Apr 2012 → Apr 2013 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01146522 | May 2010 → Oct 2011 | hyperlipoproteinemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04620161 | Sep 2020 → Apr 2022 | constipation disorder | Anji Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01811472 | Jun 2013 → Sep 2014 | NAFLD1 | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01594983 | Jun 2012 → Jul 2013 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01474434 | Dec 2011 → Jun 2014 | coronary artery disorder, hypertriglyceridemia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01387958 | Jul 2011 → Feb 2012 | hepatitis C virus infection | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00901979 | Apr 2009 → Jun 2010 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01589237 | Feb 2013 → Jul 2015 | familial chylomicronemia syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01514461 | Jul 2012 → May 2014 | familial chylomicronemia syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pradigastat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04620161 ↗ |
| Known as | Lcq-908 sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364624 ↗ |
| Known as | LCQ-908-ABA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364624 ↗ |
| Known as | LCQ-908-NXA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364624 ↗ |
| Known as | LCQ908 | “pradigastat (LCQ908)” NCT01474434 ↗ |
| Known as | Lcq908 - dgat-1-inhibitor | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364624 ↗ |
| Known as | LCQ908A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00901979 ↗ |
| Known as | PRADIGASTAT SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364624 ↗ |
| Action | Inhibit | “Diacylglycerol O-acyltransferase 1 inhibitor” CHEMBL2364624 ↗1“Diacylglycerol acyltransferase inhibitor” NCT01594983 ↗ |
| Modality | Small molecule | — CHEMBL2364624 ↗ |
| Route | Oral | “single oral dose of LCQ908” NCT01558323 ↗ |
| Target | DGAT1 | “Diacylglycerol O-acyltransferase 1 inhibitor” CHEMBL2364624 ↗ |